CML Publications February 2025
As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications from low- and middle-income countries.
Clinical publications
Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving Olverembatinib: Quality of life matters!
Eşkazan AE. Cancer, February 2025
Novel treatment strategies for chronic myeloid leukemia – Review
Cruz-Rodriguez N and Deininger MW. Blood, February 2025
Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia – Review
Guilhot F and Hehlmann R. Blood, February 2025
Unrelated bone marrow transplantation for CML after liver transplantation
Watanabe M et al. Intern Med, February 2025 (epub ahead of print)
open access publication
Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::ABL1/A337V can be effectively overcome with dasatinib treatment
Batar P et al. Curr Oncol, February 2025
open access publication
A CML patient carrying BCR::ABL1 splicing variant did not experience blast crisis for 15 years without responding to various TKIs
Nakamura F et al. Intern Med, February 2025
open access publication
Ophthalmic findings leading to diagnose chronic myeloid leukemia: A multimodal image case report
Hoyos A et al. Eur J Ophthalmol, February 2025 (epub ahead of print)
Asciminib in the treatment of chronic myeloid leukemia chronic phase – Review
Costa A et al. Future Oncol, February 2025 (epub ahead of print)
A nomogram for predicting T315I-free survival in chronic-phase chronic myeloid leukemia patients: A multicentre retrospective study
Hu SW et al. Sci Rep, February 2025
open access publication
Introduction to a series of reflections on a quarter century of TKIs for CML
Druker BJ. Blood, February 2025
open access publication
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1 / 2 trial
Cortes JE et al. Lancet Haematol, February 2025 (epub ahead of print)
Blast-phase chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia
Shuyu E et al. Am J Clin Pathol, February 2025
Inflammatory/immune adverse events in chronic myeloid leukemia patients during treatment with Bosutinib
Agostani E et al. Cancer Med, February 2025
open access publication
Total psoriasis regression in a patient with chronic myeloid leukemia treated using Nilotinib
Horňák T et al. Ann Hematol, February 2025 (epub ahead of print)
open access publication
Fibrosis and treatment-free remission in chronic myeloid leukemia
Brailovski E et al. Br J Haematol, February 2025 (epub ahead of print)
BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US Food and Drug Administration-approved droplet-based PCR assay
Kockerols C et al. J Mol Diagn, February 2025
open access publication
Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia
Abumiya M et al. Int J Hematol, February 2025 (epub ahead of print)
open access publication
Treatment-free remission outcomes in BCR::ABL1 digital PCR selected clinical cohort of chronic myeloid leukemia patients
Kockerols C et al. Eur J Haematol, February 2025 (epub ahead of print)
open access publication
Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukemia
Gong X et al. Leukemia, February 2025 (epub ahead of print)
open access publication
Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia
Chen EY et al. Eur J Haematol, February 2025
open access publication
Scientific publications
Autophagy and Cancer: Insights into molecular mechanisms and therapeutic approaches for chronic myeloid leukemia – Review
Kausar MA et al. Biomolecules, February 2025
open access publication
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
Guoyun J et al. Exp Hematol, February 2025
open access publication
MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Box, Puma and Noxa expression levels in imatinib-resistant chronic myeloid leukemia cells
Kimura A et al. Biomed Rep, February 2025
open access publication
MiR-142 deficit in T-cells during blast crisis promotes chronic myeloid leukemia immune escape
Chen F et al. Nat Commun, February 2025
open access publication
Low-dose bee venom as a potential target against human chronic myeloid leukemia cells
Halici H et al. Protein J, February 2025 (epub ahead of print)
Circumventing imatinib resistance in chronic myeloid leukemia: Novel Telmirsatan-based cell death modulators with improved activity and stability
Gebhart M et al. Eur J Med Chem, February 2025
open access publication
Proliferation inhibited by Genipin in human leukemia K562 cells: Involvement of uncoupling protein 2 in mitochondrial damage
Zhou Y et al. World J Oncol, February 2025 (epub ahead of print)
open access publication
CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR Signaling Pathway
Miyashita N et al. Cancer Sci, February 2025 (epub ahead of print)
open access publication
LMIC publications
Assessment of treatment outcomes in chronic myeloid leukemia patients on tyrosine kinase inhibitors: Insights from a resource limited setting
Awlachew WY et al. Cancer Med, February 2025
open access publication